Is there any other autoimmune disease treated by surgical removal of a gland? Does the evidence of autoimmunity in myasthenia gravis (MG) support medical treatment of significant ocular involvement? The basis for answering these questions must rest on an understanding of disease progression, the success of treatment, and the risk-benefit ratio for the patient. Although there is a high frequency of autoimmune disease in MG, there are no studies of any other autoimmune disease being treated by surgical removal of a gland or thymectomy. The surgical treatment of MG by thymectomy dates to the series of 20 patients with and without thymoma reported by Blalock1 in 1944; this treatment was innovative and was effective then and still is now, even in the immunomodulatory era. There is little doubt that the thymus is responsible for T-cell development and maintains the autoimmune response, but thymectomy for nonthymomatous MG may not offer any benefit over medical treatment alone. Myasthenia gravis respects the criteria for autoimmunity, and the suspected autoimmune pathogenesis was confirmed by anti–acetylcholine receptor (AChR) antibody identification.2 However, the natural history and degree of disease disability vs the adverse effects of medical therapy must be considered. In generalized MG (GMG), there is no debate as to the efficacy and importance of treatment.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 10
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Make the Diagnosis: Myasthenia Gravis
The Rational Clinical Examination
Original Article: Does This Patient Have Myasthenia Gravis?
All results at
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.